| Issue Date | Title | Author(s) | Source | WOS | Fulltext/Archive link |
| 2011 | Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation | Laport, G. G.; Sheehan, K.; Baker, J.; Armstrong, R.; Wong, R. M.; Lowsky, R.; Johnston, L. J.; Shizuru, J. A.; Miklos, D.; Arai, S.; Benjamin, J. E.; Wen-Kai Weng ; Negrin, R. S. | Biology of Blood and Marrow Transplantation | | |
| 2015 | Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile | Percival, M. E. M.; Medeiros, B. C.; Tian, L.; Robeson, S.; Laport, G. G.; Johnston, L. J.; Shizuru, J. A.; Miklos, D. B.; Arai, S.; Wen-Kai Weng ; Negrin, R. S.; Lowsky, R. | Bone Marrow Transplantation | | |
| 2015 | Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning | Rezvani, A. R.; Kanate, A. S.; Efron, B.; Chhabra, S.; Kohrt, H. E.; Shizuru, J. A.; Laport, G. G.; Miklos, D. B.; Benjamin, J. E.; Johnston, L. J.; Arai, S.; Wen-Kai Weng ; Negrin, R. S.; Strober, S.; Lowsky, R. | Bone Marrow Transplantation | | |
| 2018 | Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma | Spiegel, J. Y.; Sahaf, B.; Hossain, N.; Frank, M. J.; Claire, G.; Abramian, M.; Latchford, T.; Villa, B.; Cancilla, J.; Oak, J.; Natkunam, Y.; Long, S. R.; Arai, S.; Johnston, L. J.; Lowsky, R.; Meyer, E. H.; Muffly, L. S.; Negrin, R. S.; Rezvani, A. R.; Shizuru, J. A.; Wen-Kai Weng ; Kong, K. A.; Mackall, C. L.; Miklos, D. B. | Blood | | |
| 2014 | European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation | Medeiros, B. C.; Tian, L.; Robenson, S.; Laport, G. G.; Johnston, L. J.; Shizuru, J. A.; Miklos, D. B.; Arai, S.; Benjamin, J. E.; Wen-Kai Weng ; Negrin, R. S.; Lowsky, R. | Blood Cancer Journal | | |
| 2017 | HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity | Spinner, M. A.; Fernandez-Vina, M.; Creary, L. E.; Quinn, O.; Elder, L.; Arai, S.; Johnston, L. J.; Meyer, E. H.; Miklos, D. B.; Muffly, L. S.; Negrin, R. S.; Shizuru, J. A.; Wen-Kai Weng ; Laport, G. G.; Strober, S.; Lowsky, R.; Rezvani, A. R. | Blood Advances | | |
| 2016 | Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma | Neppalli, A. K.; Shizuru, J.; Johnston, L. J.; Muffly, L. S.; Wen-Kai Weng ; Negrin, R.; Meyer, E.; Laport, G.; Lowsky, R.; Arai, S.; Miklos, D. B.; Rezvani, A. R. | Journal of Clinical Oncology | | |
| 2018 | Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort | Spinner, M. A.; Kennedy, V. E.; Tamaresis, J. S.; Lavori, P. W.; Elder, L. V.; Arai, S.; Johnston, L. J.; Meyer, E. H.; Miklos, D. B.; Muffly, L. S.; Negrin, R. S.; Rezvani, A. R.; Shizuru, J. A.; Wen-Kai Weng ; Hoppe, R. T.; Strober, S.; Lowsky, R. | Blood | | |
| 2019 | Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort | Spinner, M. A.; Kennedy, V. E.; Tamaresis, J. S.; Lavori, P. W.; Arai, S.; Johnston, L. J.; Meyer, E. H.; Miklos, D. B.; Muffly, L. S.; Negrin, R. S.; Rezvani, A. R.; Shizuru, J. A.; Wen-Kai Weng ; Hoppe, R. T.; Strober, S.; Lowsky, R. | Blood Advances | | |
| - | Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma | Lemieux, C.; Muffly, L. S.; Rezvani, A.; Lowsky, R.; Iberri, D. J.; Craig, J. K.; Frank, M. J.; Johnston, L. J.; Liedtke, M.; Negrin, R.; Wen-Kai Weng ; Meyer, E.; Shizuru, J.; Shiraz, P.; Arai, S.; Miklos, D. B.; Sidana, S. | Bone Marrow Transplantation | | |
| 2010 | Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma | Arai, S.; Letsinger, R.; Wong, R. M.; Johnston, L. J.; Laport, G. G.; Lowsky, R.; Miklos, D. B.; Shizuru, J. A.; Wen-Kai Weng ; Lavori, P. W.; Blume, K. G.; Negrin, R. S.; Horning, S. J. | Biology of Blood and Marrow Transplantation | | |
| 2012 | Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence | Arai, S.; Sahaf, B.; Narasimhan, B.; Chen, G. L.; Jones, C. D.; Lowsky, R.; Shizuru, J. A.; Johnston, L. J.; Laport, G. G.; Wen-Kai Weng ; Benjamin, J. E.; Schaenman, J.; Brown, J.; Ramirez, J.; Zehnder, J. L.; Negrin, R. S.; Miklos, D. B. | Blood | | |
| 2012 | Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma | Chen, A. I.; Negrin, R. S.; McMillan, A.; Shizuru, J. A.; Johnston, L. J.; Lowsky, R.; Miklos, D. B.; Arai, S.; Wen-Kai Weng ; Laport, G. G.; Stockerl-Goldstein, K. | Bone Marrow Transplantation | | |
| 2009 | TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors | Kohrt, H. E.; Turnbull, B. B.; Heydari, K.; Shizuru, J. A.; Laport, G. G.; Miklos, D. B.; Johnston, L. J.; Arai, S.; Wen-Kai Weng ; Hoppe, R. T.; Lavori, P. W.; Blume, K. G.; Negrin, R. S.; Strober, S.; Lowsky, R. | Blood | | |
| 2016 | Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation | Veeraputhiran, M.; Arai, S.; Lowsky, R.; Miklos, D. B.; Meyer, E.; Muffly, L. S.; Negrin, R.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Johnston, L. J. | Journal of Clinical Oncology | | |
